Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
29/09/2026 12:07
BRIEF-Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis Sept 29 (Reuters) - Beyondspring Inc BYSI.O:
BEYONDSPRING ANNOUNCES FDA FAST TRACK DESIGNATION FOR PLINABULIN IN POST-ICI NON-SQUAMOUS NSCLC AND STRATEGIC TRANSACTION TO ADVANCE GLOBAL PHASE 3 DUBLIN-4 TRIAL TOWARD PLANNED INTERIM ANALYSIS
BEYONDSPRING - SELLS MAJORITY EQUITY INTEREST IN CHINESE SUBSIDIARY TO FUND DUBLIN-4 TRIAL IN CHINA
BEYONDSPRING - RETAINS GLOBAL RIGHTS TO PLINABULIN OUTSIDE GREATER CHINA
Source text: ID:nGNXbkTTLj
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value